BioLine RX Ltd - Asset Resilience Ratio

Latest as of September 2025: 43.46%

BioLine RX Ltd (BLRX) has an Asset Resilience Ratio of 43.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BLRX total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

ILA17.30 Million

≈ $46.38K USD Cash + Short-term Investments

Total Assets

ILA39.80 Million

≈ $106.71K USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2024)

This chart shows how BioLine RX Ltd's Asset Resilience Ratio has changed over time. See BLRX net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down BioLine RX Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BLRX company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA17.30 Million	43.46%
Total Liquid Assets	ILA17.30 Million	43.46%

Asset Resilience Insights

Very High Liquidity: BioLine RX Ltd maintains exceptional liquid asset reserves at 43.46% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

BioLine RX Ltd Industry Peers by Asset Resilience Ratio

Compare BioLine RX Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	Biotechnology	63.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bio-Thera Solutions Ltd SHG:688177	Biotechnology	4.09%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Gubra A/S CO:GUBRA	Biotechnology	79.61%

Annual Asset Resilience Ratio for BioLine RX Ltd (2006–2024)

The table below shows the annual Asset Resilience Ratio data for BioLine RX Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	23.46%	ILA9.13 Million ≈ $24.47K	ILA38.91 Million ≈ $104.31K	-37.14pp
2023-12-31	60.60%	ILA38.74 Million ≈ $103.86K	ILA63.92 Million ≈ $171.38K	+7.59pp
2022-12-31	53.02%	ILA40.49 Million ≈ $108.57K	ILA76.38 Million ≈ $204.78K	-1.22pp
2021-12-31	54.24%	ILA44.15 Million ≈ $118.35K	ILA81.39 Million ≈ $218.21K	+42.07pp
2020-12-31	12.17%	ILA5.76 Million ≈ $15.43K	ILA47.29 Million ≈ $126.78K	-29.26pp
2019-12-31	41.43%	ILA22.19 Million ≈ $59.50K	ILA53.57 Million ≈ $143.61K	-6.14pp
2018-12-31	47.56%	ILA26.75 Million ≈ $71.71K	ILA56.23 Million ≈ $150.76K	-25.22pp
2017-12-31	72.78%	ILA44.37 Million ≈ $118.96K	ILA60.97 Million ≈ $163.45K	-12.36pp
2016-12-31	85.14%	ILA33.15 Million ≈ $88.88K	ILA38.94 Million ≈ $104.39K	+3.04pp
2015-12-31	82.10%	ILA42.12 Million ≈ $112.92K	ILA51.30 Million ≈ $137.54K	+2.32pp
2014-12-31	79.78%	ILA28.85 Million ≈ $77.36K	ILA36.17 Million ≈ $96.96K	+33.22pp
2013-12-31	46.56%	ILA9.29 Million ≈ $24.90K	ILA19.95 Million ≈ $53.48K	+33.94pp
2012-12-31	12.62%	ILA3.07 Million ≈ $8.22K	ILA24.31 Million ≈ $65.17K	-46.29pp
2011-12-31	58.91%	ILA17.28 Million ≈ $46.34K	ILA29.34 Million ≈ $78.65K	+40.78pp
2010-12-31	18.13%	ILA28.04 Million ≈ $75.17K	ILA154.61 Million ≈ $414.51K	-8.56pp
2008-12-31	26.69%	ILA30.89 Million ≈ $82.81K	ILA115.73 Million ≈ $310.26K	+25.11pp
2007-12-31	1.58%	ILA3.27 Million ≈ $8.78K	ILA207.88 Million ≈ $557.33K	-12.33pp
2006-12-31	13.91%	ILA2.80 Million ≈ $7.50K	ILA20.12 Million ≈ $53.95K	--

pp = percentage points

About BioLine RX Ltd

TA:BLRX Israel Biotechnology

Market Cap

$9.10 Million

ILA3.39 Billion ILA

Market Cap Rank

#27266 Global

#392 in Israel

Share Price

ILA1.30

Change (1 day)

-7.14%

52-Week Range

ILA1.20 - ILA3.70

All Time High

ILA618.30